Guard Therapeutics International AB (DE:5LH0)
FRANKFURT:5LH0
Want to see DE:5LH0 full AI Analyst Report?
5LH0 Stock Chart & Stats
€0.04
€0.06(3.57%)
At close: 4:00 PM EST
€0.04
€0.06(3.57%)
Day’s Range― - ―
52-Week Range€0.01 - €2.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.30M
Enterprise Value-€14.01M
Total Cash (Recent Filing)€40.99M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-56.32
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding20,167,631
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform-focused R&D (A1M)A platform built around A1M provides durable R&D leverage: the same biology can support multiple indications or candidates, raising potential upside from one discovery program across kidney disorders and creating a structural competitive moat if clinical data validate the mechanism.
No Reported DebtComplete absence of debt materially reduces refinancing and interest burdens, giving management more flexibility for R&D spending and financing choices. For an early-stage biotech, this structurally lowers near-term default risk and preserves operational optionality.
Cash-flow Aligns With Reported LossesWhen operating cash flow tracks accounting losses, it signals transparent cash consumption rather than hidden non-cash accounting effects. That alignment aids realistic runway forecasting and capital planning, a durable advantage for monitoring funding needs and timing future financings.
Bears Say
No Revenue; Persistent Large LossesAbsence of any revenue over multiple years means the business is entirely pre-commercial and reliant on external funding. Persistent, large losses erode capital and increase the probability of dilution or program cutbacks absent material clinical or partnership progress over the medium term.
High And Rising Cash BurnSustained, very large negative operating and free cash flows are depleting liquidity quickly. This structural cash burn forces frequent capital raises, raises execution risk, and increases the likelihood of dilution or program delays absent near-term catalytic events or partnership funding.
Material Decline In Equity And AssetsA rapid drop in equity and total assets over a few years shrinks the balance-sheet buffer against setbacks. Reduced asset and equity base lowers financial resilience, limits strategic optionality, and makes the company more vulnerable to adverse trial outcomes or funding market shifts.
5LH0 FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was €0.01 and its highest was €2.27 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is €2.30M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Aug 20, 2026 which is in 88 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on May 13, 2026. The company reported -€0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.029.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -€0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in DE:5LH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―